EureKare

Biomemory is a deep-tech company focusing on innovative data storage solutions for large enterprises and institutions. It leverages molecular engineering to create cost-effective, energy-efficient appliances that enable exabyte-scale storage. The company's advanced data storage drives utilize a biobased system that encodes substantial amounts of data on long DNA strands, significantly surpassing the capacity of traditional storage methods such as solid-state drives and magnetic tapes. Biomemory's technology offers remarkable durability, ensuring data stability at ambient temperatures without the need for energetic input or CO2 emissions, making it an environmentally friendly choice. This approach provides researchers and organizations with a long-lasting storage solution, capable of preserving information for thousands of years.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Gynov develops innovative solutions in women's health, including the scientific development and application of dietary supplements. The company uses a multi-target, holistic approach with carefully selected ingredients and research-based formulations to support women through puberty, pregnancy, postpartum, and the peri- and post-menopausal stages.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

Omne Possibile is a biotechnology company focused on developing new-to-nature nucleic acids, specifically XNA, which surpass traditional DNA and RNA technologies. The company provides a range of services in XNA development, including chemical synthesis, genetics, directed evolution of enzymes and genomes, automated molecule design, and bioproduction pathways. By leveraging these capabilities, Omne Possibile aims to enhance various sectors such as healthcare, information technology, and smart materials. Their innovative approach enables industries to optimize data storage and therapeutic applications by adapting the chemical formats of genetic information to meet specific process requirements.